Les récentes recherches suggèrent que la superovulation de vaches laitières sous une concentration élevée de progestérone permet de meilleurs résultats que la superovulation sous une basse progestéronémie pendant la première vague folliculaire. Nous émettions donc l’hypothèse qu’une basse progestéronémie pendant la phase lutéale, une problématique connue chez la vache laitière haute productrice, compromet le rendement en embryons suite à la superovulation de la deuxième vague folliculaire. Afin de tester cette hypothèse, 18 vaches laitières ont été superovulées à deux reprises avec deux protocoles distincts, dont un atteignant un niveau lutéal de progestérone (>2.5 ng/mL, le corps jaune comme source de progestérone) et l’autre un niveau sublutéal (<2.5 ng/mL, l’implant intravaginal comme unique source de progestérone). Le nombre d’embryons transférables était similaire entre les protocoles. Curieusement, nous avons obtenu un développement accéléré des follicules dans le protocole sublutéal (p = 0,002), un développement embryonnaire plus avancé (p = 0,01) et une qualité améliorée des embryons (p = 0,02) par rapport au protocole lutéal. Ces résultats suggèrent que des facteurs autres qu’une basse progestéronémie peuvent affecter le rendement en embryons. Une pulsatilité augmentée de la LH grâce à une basse progestéronémie pendant la deuxième vague folliculaire pourrait être responsable du développement folliculaire accru ainsi que du développement et de la qualité augmentés des embryons. Ces résultats indiquent que des niveaux sublutéaux de progestérone pendant la phase lutéale ne compromettent pas le résultat d’un traitement de superovulation mais, au contraire, peuvent améliorer certains aspects du rendement en embryons. / Recent research has suggested that superovulation of dairy cows under high levels of progesterone allows for better results than superovulation of cows under low levels during the first follicular wave. We therefore hypothesized that low levels of luteal progesterone, a known problem for high producing dairy cows, impair superovulatory outcome during the second follicular wave. To test this hypothesis, 18 lactating cows were superovulated twice with two different protocols, one creating a luteal level of progesterone (>2.5 ng/mL, corpus luteum as progesterone source) during the superovulation treatment, the other one inducing a subluteal level (<2.5 ng/mL, intravaginal implant as the only progesterone source). The number of transferable embryos was not significantly different between the two protocols. Interestingly, we obtained an accelerated development of follicles in the subluteal protocol (p = 0.002), a more advanced embryo development (p = 0.01) and enhanced embryo quality (p = 0.02) compared to the luteal protocol. These results indicate that factors other than low progesterone levels may determine the outcome of superovulation performed during the first follicular phase. Increased LH pulsatility in response to low levels of progesterone during the second follicular phase may be responsible for enhancing follicular development in our subluteal group, resulting in accelerated embryo development and improved embryo quality. These results indicate that subluteal levels of progesterone during the luteal phase do not impede superovulatory outcome, but may, in contrary, enhance certain aspects of the yield in embryos.

Clinical immunohistochemistry (IHC) techniques are not yet fully standardized. In this project, a standardization method was developed and tested for proficiency testing (PT) in external quality assurance (EQA) and quality control (QC) in clinical IHC laboratories. The breast cancer markers estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2) were used as a model system. Digital image analysis (IA) was used in conjunction with new calibrated and standardized cell line microarrays (CLMA). CLMAs built from nine formalin-fixed paraffin-embedded (FFPE) breast cancer cell lines were used for both QC controls and PT samples, instead of traditionally used FFPE tissues, in the standardization of breast cancer IHC. IA was used for measurement of IHC results, and compared to evaluation by the traditional expert-assessment method. Laboratory Score: Reference Score Ratio (LSRSR) was derived from Histo-Scores (HScores) determined by IA. HScores and LSRSRs were examined statistically and evaluated as histograms and boxplots to summarize and rank participant laboratory EQA results, in comparison to a reference sample or reference laboratories in two consecutive Canada-wide EQA runs. LSRSR-derived reference ranges were highly sensitive in evaluating laboratory EQA performance in PT as well as for monitoring of controls for QC. Laboratory on-slide tissue and cell-line IHC QA controls were assessed using IA and Levey Jennings QC charts. These charts were determined to be an excellent way to observe trending in laboratory IHC staining over time, particularly when cell line controls were used. This approach also reduced the time and labor costs for PT evaluation. Overall, cell line calibration controls were functionally equivalent or better than tissue-based controls in QC and PT mainly because of cell line biological homogeneity and sample availability. This study identified an optimal design for preparation of IHC cell line controls and PT samples for breast cancer markers. Optimal, intermediate staining cell line IHC controls were identified for all three breast cancer markers. Using IA with LSRSR and cell line samples is recommended for standardization of IHC methodology. This approach advances QA for diagnostic IHC and when implemented will improve patient care

Les récentes recherches suggèrent que la superovulation de vaches laitières sous une concentration élevée de progestérone permet de meilleurs résultats que la superovulation sous une basse progestéronémie pendant la première vague folliculaire. Nous émettions donc l’hypothèse qu’une basse progestéronémie pendant la phase lutéale, une problématique connue chez la vache laitière haute productrice, compromet le rendement en embryons suite à la superovulation de la deuxième vague folliculaire. Afin de tester cette hypothèse, 18 vaches laitières ont été superovulées à deux reprises avec deux protocoles distincts, dont un atteignant un niveau lutéal de progestérone (>2.5 ng/mL, le corps jaune comme source de progestérone) et l’autre un niveau sublutéal (<2.5 ng/mL, l’implant intravaginal comme unique source de progestérone). Le nombre d’embryons transférables était similaire entre les protocoles. Curieusement, nous avons obtenu un développement accéléré des follicules dans le protocole sublutéal (p = 0,002), un développement embryonnaire plus avancé (p = 0,01) et une qualité améliorée des embryons (p = 0,02) par rapport au protocole lutéal. Ces résultats suggèrent que des facteurs autres qu’une basse progestéronémie peuvent affecter le rendement en embryons. Une pulsatilité augmentée de la LH grâce à une basse progestéronémie pendant la deuxième vague folliculaire pourrait être responsable du développement folliculaire accru ainsi que du développement et de la qualité augmentés des embryons. Ces résultats indiquent que des niveaux sublutéaux de progestérone pendant la phase lutéale ne compromettent pas le résultat d’un traitement de superovulation mais, au contraire, peuvent améliorer certains aspects du rendement en embryons. / Recent research has suggested that superovulation of dairy cows under high levels of progesterone allows for better results than superovulation of cows under low levels during the first follicular wave. We therefore hypothesized that low levels of luteal progesterone, a known problem for high producing dairy cows, impair superovulatory outcome during the second follicular wave. To test this hypothesis, 18 lactating cows were superovulated twice with two different protocols, one creating a luteal level of progesterone (>2.5 ng/mL, corpus luteum as progesterone source) during the superovulation treatment, the other one inducing a subluteal level (<2.5 ng/mL, intravaginal implant as the only progesterone source). The number of transferable embryos was not significantly different between the two protocols. Interestingly, we obtained an accelerated development of follicles in the subluteal protocol (p = 0.002), a more advanced embryo development (p = 0.01) and enhanced embryo quality (p = 0.02) compared to the luteal protocol. These results indicate that factors other than low progesterone levels may determine the outcome of superovulation performed during the first follicular phase. Increased LH pulsatility in response to low levels of progesterone during the second follicular phase may be responsible for enhancing follicular development in our subluteal group, resulting in accelerated embryo development and improved embryo quality. These results indicate that subluteal levels of progesterone during the luteal phase do not impede superovulatory outcome, but may, in contrary, enhance certain aspects of the yield in embryos.

Angiogenesis is thought to play a pivotal role in the cycling endometrium. Coordinated by oestrogen and progesterone, endometrial blood vessel development is primarily mediated by vascular endothelial growth factor-A (VEGF-A), which promotes endothelial cell (EC) proliferation and protects ECs from induced apoptosis. Studying changes at transcript level in human endometrial endothelial cells (HEECs) in response to mitogenic and inhibitory stimuli is one way towards understanding the regulation of physiological endometrial angiogenesis. Endometriosis, the presence of endometrial-like tissue outside the uterine cavity, is a common gynaecological disorder in women of reproductive age, often causing pelvic pain and reduced fertility. Chronic inflammation in the peritoneal environment and defective endometrial protein expression are some of the contributors to the complex pathophysiology of endometriosis. The aim of this work was to study the changes in the transcriptome induced by VEGF-A and partial serum deprivation in primary HEECs, and to investigate biochemical factors associated with subfertility and chronic pelvic pain in endometriosis patients. Exposing primary HEECs to VEGF-A, and serum withdrawal was found to regulate transcripts associated with survival, migration, apoptosis and progression through the cell cycle, when assessed using microarray technology and bioinformatic tools. A subset of 88 transcripts was reciprocally regulated under the two experimental conditions; thus probably important in HEEC biology. Higher endometrial epithelial staining scores of oestrogen receptor-α and reduced staining of progesterone receptors were seen in subfertile endometriosis patients. Lower levels of the receptivity biomarker leukaemia inhibitory factor (LIF) and its receptor, as well as signs of dysregulated αB-crystallin expression and increased peritoneal fluid concentrations of interleukin (IL)-1α and IL-6 were associated with reduced pregnancy rates. Endometriosis patients with chronic pelvic pain had higher levels of vasoactive intestinal peptide (VIP) in eutopic endometria and in endometriotic lesions compared with patients without chronic pain. The presence of chronic pelvic pain was also associated with increased concentrations of VIP and IL-6 in peritoneal fluid. The present results may constitute a basis for further investigation of regulatory pathways in endometrial angiogenesis as well as for studies of endometrial receptivity and pain in women with endometriosis.

O diabetes gestacional (DG) é uma condição definida como intolerância a carboidratos e hiperglicemia, com início no segundo trimestre da gravidez. Trabalhos desenvolvidos por nosso grupo mostraram que a progesterona (PG) é capaz de causar a morte de células pancreáticas, por um mecanismo dependente da geração de radicais livres, o que poderia contribuir para o desenvolvimento do DG. O objetivo desse trabalho foi estudar o efeito da PG, na presença ou não de antioxidantes, na expressão de genes relacionados ao estresse oxidativo e na defesa oxidante em células pancreáticas da linhagem RINm5F. As células foram incubadas com PG 0,1, 1,0 e 100 &#181M por 6 ou 24 h, na presença ou não dos antioxidantes vitamina E e C. Após a incubação, foram realizados ensaios de viabilidade celular e fragmentação do DNA. A PG, não causou perda da integridade da membrana das células RINm5F, porém, ela promoveu fragmentação do DNA em, aproximadamente, 40% das células RINm5F e MCF-7 (controle positivo), enquanto que os antioxidantes vitamina E e C reduziram tal fragmentação. A partir da extração do RNA e síntese de cDNA foi investigada a expressão de 84 genes envolvidos no estresse oxidativo e defesa antioxidante. Dos 84 genes, cinco deles tiveram sua expressão aumentada em no mínimo, duas vezes em, pelo menos, duas concentrações diferentes, independentemente do tempo de incubação, ou nas mesmas concentrações em tempos diferentes, como os que codificam para a proteína de choque térmico a1a (Hspa1a), glutationa peroxidase 6 (Gpx6), dual oxidase 1 (Duox1), heme oxigenase 1(Hmox1) e estearoil-CoA desaturase 1 (Scd1). Esses genes, juntamente com a peroxirredoxina 4 (Prdx4), desempenham importante papel na fisiologia da célula pancreática e/ou DG. A expressão desses genes também foi estudada na pré-incubação das células RINm5F com as vitaminas E e C. Tais antioxidantes, de forma geral, foram capazes de aumentar a expressão de Hmox1 e Prdx4, genes com funções antioxidantes, e de diminuir de Scd1, um gene com função pró- oxidante. Ao nível citoplasmático, verificou-se que as quantidades das proteínas Hmox1 e Prdx4 também foram moduladas pela da PG e/ou vitamina E e C. Os resultados sugerem que esses antioxidantes apresentam importante papel na proteção da células RINm5F contra o dano oxidativo induzido pela PG. Desta forma, os resultados obtidos nesse projeto, em conjunto, devem colaborar para melhor compreensão da patogênese do DG, abrindo novas perspectivas não só para elucidação do mecanismo molecular envolvido na ação da PG sobre células pancreáticas e sua relação com o DG, mas para o desenvolvimento de estratégias de prevenção e tratamento dessa doença baseadas na terapia com antioxidantes / Gestational diabetes (GD) is a condition defined as carbohydrate intolerance and hyperglycemia, beginning in the second trimester of pregnancy. Studies developed by our group have shown that progesterone (PG) is able to cause pancreatic cells death, by a mechanism dependent on the generation of free radicals, which could contribute to the development of GD. The aim of this work was to study the effect of PG, in the presence or absence of antioxidants, on the expression of genes related to oxidative stress and oxidant defense in pancreatic cells of the RINm5F lineage. Cells were incubated with 0.1, 1.0 and 100 µM PG for 6 or 24 h, in the presence or absence of vitamin E and C antioxidants. PG did not cause loss of membrane integrity of RINm5F cells, however, it promoted DNA fragmentation in approximately 40% of the RINm5F and MCF-7 cells (positive control), whereas vitamin E and C antioxidants reduced such fragmentation. From the RNA extraction and cDNA synthesis was investigated the expression of 84 genes involved in oxidative stress and antioxidant defense. Among of 84 investigated genes, five of them had their expression increased, in the minimum 2-fold in, at least, two different concentrations independent of incubation time (6 or 24 h), or at the same concentrations at different times, such as those that encoding for heat shock protein a1a (Hspa1a), glutathione peroxidase 6 (Gpx6), dual oxidase 1 (Duox1), heme oxygenase 1 (Hmox1) and stearoyl-CoA denaturase 1 (Scd1). These genes, together with the peroxiredoxin 4 (Prdx4), play an important role in pancreatic cell physiology and/or DG. The gene expression was also studied in the preincubation of RINm5F cells with vitamin E and C. These antioxidants were generally able to increase the Hmox1 and Prdx4 expression, genes with antioxidant functions, and decrease the Scd1 expression, a gene with pro-oxidant function. At the cytoplasmic level, it was found that the amounts of Hmox1 and Prdx4 proteins were also modulated by PG and / or vitamin E and C. The results suggest that these antioxidants play an important role in the RINm5F protection cells against the oxidative damage induced by PG. Thus, the results obtained in this project, together, should contribute to a better understanding of the pathogenesis of DG, opening new perspectives not only to elucidate the molecular mechanism involved in the action of PG on pancreatic cells and its relationship with DG, but for the development of strategies for the prevention and treatment of this disease based on antioxidant therapy

Objetivos: O presente estudo teve como objetivo comparar a frequência das contrações uterinas em gestações gemelares em uso da progesterona natural e de placebo. Método: Estudo randomizado, duplo-cego, placebo controlado, realizado no período de 01 de junho de 2007 a 31 de outubro de 2013. Participaram do estudo 341 gestantes, com 170 randomizadas no grupo progesterona e 171 no grupo placebo. Todas as gestantes realizaram exame de tocografia no período de 24 a 34 semanas e 6 dias, com duração de trinta minutos, a cada três semanas. A contração uterina foi definida como uma elevação da linha de base com amplitude acima de 5 mm e duração mínima de trinta segundos. Na comparação da frequência das contrações uterinas entre os grupos, nas diferentes idades gestacionais, utilizou-se o teste t de Student. O modelo de análise GEE - modelo generalizado de equações de estimação - foi utilizado na comparação, entre os grupos, da frequência das contrações uterinas em relação à idade gestacional no parto, e também na avaliação da interação da frequência das contrações uterinas com a medida do colo uterino e a corionicidade. Resultados: As características epidemiológicas e gerais das gestantes foram semelhantes nos dois grupos. A frequência média das contrações uterinas diferiu entre os grupos apenas na 34ª semana (P = 0,005), com frequência maior de contrações no grupo progesterona (4,81±3,24) em relação ao grupo placebo (2,73 ± 2,06). Não houve diferença significativa na comparação da frequência média das contrações uterinas e a idade gestacional no parto (< 28 sem, < 32 sem, < 34 sem e < 37 semanas) entre os grupos. Não foi observada interação da frequência das contrações uterinas com a medida do colo uterino ou com a corionicidade da gestação, em relação aos grupos progesterona ou placebo. Conclusão: O uso da progesterona natural não interfere na frequência das contrações uterinas nas gestações gemelares abaixo de 34 semanas gestacionais / Objectives: The aim of this study was to comparate uterine contraction frequency in twin pregnancies in use of natural progesterone and placebo. Methods: Randomized, double-blind, placebo-controlled study, conducted between June 1, 2007 to October 31, 2013. The study included 341 twin pregnancies, with 170 randomized in the progesterone group and 171 in the placebo group. All pregnancies had uterine contraction registration by tocodinamometry every three weeks, during 30 minutes between 24 to 34 weeks and 6 days. Uterine contraction was defined as an amplitude greater than 5 mm, from baseline registration, and a duration longer than 30 seconds. Comparison of contraction frequency between the groups at different gestational ages was examined using the parametric student t test. The model GEE - generalized estimating equation model - was used in the comparison, between the groups, the uterine contraction frequency according gestational age at delivery, and also for evaluating the interaction of the frequency contractions with cervical length and chorionicity. Results: Epidemiological and general characteristics of the pregnant woman were similar in both groups. At the 34 weeks, was only gestational age that presented difference (P = 0.005) in the mean uterine contraction frequency between progesterone (4.81 ± 3.24) and placebo (2.73 ± 2.06) groups. No difference in the mean uterine contraction frequency was observed between progesterone and placebo groups in relation to gestational age at delivery. Cervical length measurement and chorionicity did not influence the uterine contraction frequency according to progesterone or placebo. Conclusion: The use of natural progesterone in twin pregnancies does not affect the uterine contraction frequency before 34 weeks gestation

O objetivo do experimento I foi avaliar a luteólise causada por três doses de PGF2&#945; (12,5; 25 e 50 mg de Dinoprost tometamina) nos dias 5 e 7 do ciclo estral. Foram utilizadas 339 vacas não lactantes da raça Nelore. Os animais foram divididos em dois grupos de acordo com a apresentação do estro, recebendo a dose de PGF2&#945; nos dias 5 e 7 do ciclo estral. Cada grupo foi subdividido em três, que receberam os seguintes tratamentos de PGF2&#945; (12,5 mg; 25 mg; 50 mg). Através da concentração de P4 foram estimadas as taxas de regressão luteal 1 e 0,5 (1 - animais com concentração de P4 abaixo de 1 ng/mL; 0,5 animais com concentração de P4 abaixo de 0,5 ng/mL). Não houve interação entre a dose de PGF2&#945; e o dia do ciclo estral. A aplicação de PGF2&#945; no dia 7 do ciclo estral apresentou maior taxa de regressão luteal 1 e 0,5 quando comparada com o dia 5 do ciclo estral (1 - 76,9 vs 37,0 % - P = 0,0001; 0,5 - 57,5 vs 21,7 %, P = 0,0001, respectivamente). A taxa de regressão luteal 1 aumentou de acordo com a dose de PGF2&#945; administrada (12,5 mg 39,0 %; 25 mg 56,9 %; 50 mg 76,5 % P <0,0001). Quando a PGF2&#945; foi administrada no dia 5 do ciclo estral a concentração média de P4 segui o padrão de luteólise parcial e foi dependente da dose de PGF2&#945;. Quando a PGF2&#945; foi aplicada no dia 7 do ciclo estral a concentração média de P4 caiu drasticamente de 0 para 24 h e não voltou a se elevar em 48 h. A concentração de P4 em 48 h após a aplicação de PGF2&#945; foi menor na dose de 50 mg (0,51 ± 0,07 ng/mL). A taxa de luteólise foi menor no dia 5 do ciclo estral comparado com o dia 7 do ciclo estral. À medida que a dose de PGF2&#945; foi aumentada, a porcentagem de regressão luteal se elevou. O objetivo do experimento II foi avaliar se a substituição das aplicações do GnRH por BE, ECP e eCG no protocolos de 5 dias de P4 causa dupla ovulação e se a utilização de 1 ou 2 mg de BE no início do protocolo influencia na taxa de ovulação dupla. Foram utilizadas 85 multíparas da raça Nelore. No dia 0 do protocolo, as vacas receberam um implante de P4 e a dose de BE segundo o tratamento pertencente (tratamento A 1 mg de BE, tratamento B 2 mg de BE). Cinco dias após, o dispositivo foi retirado e aplicou-se PGF2&#945;, ECP eCG. Houve 5,9 % de dupla ovulação. O tratamento A causou menor porcentagem folículos maiores que 8 mm no dia 7 protocolo que o tratamento B (28,7 vs 50,6 P = 0,0460). Não houve diferença significativa na taxa de ovulação dupla, no diâmetro do folículo dominante no dia 5 e no dia 7 do protocolo e na taxa de crescimento folicular entre os tratamentos A e B. O protocolo de 5 dias de P4 com BE, ECP e eCG causou uma baixa taxa de dupla ovulação. O objetivo do experimento III foi comparar o aparecimento e a frequência de estro e a taxas de ovulação e gestação entre os protocolos de 5 dias de P4 + GnRH / GnRH e de 7 dias de P4 + BE / ECP + eCG em nulíparas, primíparas e multíparas. Foram utilizadas 411 fêmeas da raça Nelore (nulíparas - n = 198; primíparas - n = 80; multíparas - n = 133). No protocolo de 7 dias de P4, os animais receberam no dia 0 um implante de P4 e BE. No dia 7, o dispositivo foi retirado e aplicou-se PGF2&#945;, ECP e eCG. No protocolo de 5 dias de P4, os animais receberam no dia 0 o implante de P4 e GnRH. No dia 5, o dispositivo foi retirado e aplicaram-se 2 doses de PGF2&#945; com intervalo de 6 h entre as doses de PGF2. Os animais que não apresentaram estro até a hora da IA receberam 100 &#956;g de GnRH no momento da IA. A taxa de prenhez utilizando o protocolo de 5 ou 7 dias de P4 variou de acordo com a categoria da fêmea (nulíparas - 41,0 vs 51,0 % - P = 0.1608; primíparas 25,6 vs 31,7 % - P = 0,5513; multíparas - 58,4 vs 32,8 % - P = 0,0041, respectivamente). A taxa de apresentação de estro no protocolo de 7 dias de P4 foi maior para todas as categorias de fêmeas quando comparado com o protocolo de 5 dias deP4. (nulíparas 95,8 vs 66,0 % - P <0,0001; primíparas 48,7 vs 0 %; multíparas - 76,9 vs 13,4 % - P <0,0001, respectivamente). A resposta ao protocolo de 5 dias com GnRH foi pior nas multíparas. / The objective of the experiment I was to evaluate the luteolysis caused by three doses of PGF2&#945; (12.5, 25 and 50 mg of Dinoprost tometamina) when applied on the 5th and 7th days of the estrous cycle. Three hundred thirty-nine (339) nonlactating Nelore cows were used. The animals were divided into two groups according to the onset of estrus, and received the PGF2&#945; dose on the 5th or 7th day of the estrous cycle. Each group was divided into three subgroups, which were submitted to the treatments of PGF2&#945; with dose of 12.5 mg, 25 mg or 50 mg. Through the P4 concentration, the rates of 1 and 0.5 luteal regression were estimated (1 - animals with P4 concentration below 1 ng/mL and 0.5 - animals with P4 concentration below 0.5 ng/mL). There was no interaction between the PGF2&#945; dose and the day of the estrous cycle. The PGF2&#945; application on the 7th day of the estrous cycle had higher rates of the 1 and 0.5 luteal regression, when compared to the PGF2&#945; application on the 5th day of the estrous cycle (1 - 76.9 vs 37.0 % - P = 0.0001; 0,5 - 57.5 vs 21.7 %, P = 0.0001, respectively). The rate of 1 luteal regression increased with the PGF2&#945; dose (12.5 mg - 39.0 %; 25 mg - 56.9 %; 50 mg - 76.5 %, P < 0.0001). The average concentrations of P4, when the PGF2&#945; was administered on the 5th day of the estrous cycle, follow the partial luteolysis standard that dependent on the PGF2&#945; dose. When the PGF2&#945; is applied on 7th day of the estrous cycle, the average concentration of P4 drops dramatically from 0 to 24 h and it do not rise again in 48 h. The P4 concentration is lower in the 50 mg (0.51 ± 0.07 ng/mL), 48 h after the PGF2&#945; application. The luteolysis rate was low on the 5th day of the estrous cycle. The luteal regression percentage increased with increase of the PGF2&#945; dose. The objective of the experiment II was to evaluate whether the replacement of the GnRH applications by BE, ECP and eCG in the 5-day protocols of P4 cause double ovulation and if the use of 1 or 2 mg of BE at the beginning of the protocol influences the double ovulation rate. Eighty-five (85) multiparous Nelore cows were used. On day 0 of the protocol, the cows received a P4 implant and a dose of BE that depending on the treatment to which the cows belong (Treatment A - 1 mg of BE, treatment B - 2 mg of BE). Five days later, the device was removed and the PGF2&#945;, ECP and eCG were applied. In the experiment II, there was 6.5 % of double ovulation. There was no significant difference in the double ovulation rate, dominant follicle diameter on the 5th and 7th day of the protocols, and follicular growth rate between the treatments A and B. The 5-day protocol of P4 with BE, eCG and ECP caused a low rate of the double ovulation, and there was no difference between 1 or 2 mg of BE to synchronize the follicular development wave. The objective of the experiment III was to compare the onset and frequency of estrus and the ovulation and pregnancy rates among the protocols of 5 days of P4 with GnRH and 7 days of P4 with BE, ECP and eCG in nulliparous, primiparous and multiparous. Four hundred eleven (411) Nellore females were used (nulliparous - n = 198; primiparous - n = 80; multiparous - n = 133). In 7-day protocol of P4, the animals received an implant of P4 and BE on day 0. On day 7, the device was removed and the PGF2&#945;, ECP and eCG were applied in the cows. In 5-day protocol of P4, the animals received implants of GnRH and P4 on the day 0. On day 5, the device was removed and two doses of PGF2&#945; were applied with interval of 6 h. The animals that did not show estrus until the AI time received 100 mg of GnRH at this moment. The pregnancy rate varied according to the female category in both protocols (nulliparous - 41.0 vs 51.0 % - P = 0.1608; primiparous - 25.6 vs 31.7 % - P = 0.5513; multiparous - 58.4 vs 32.8 % - P = 0.0041, respectively). The rate estrus onset in the 5-day protocol of P4 with GnRH was lower for all female categories, when compared to the 7-day protocol (nulliparous - 95.8 vs 66.0 % - P <0.0001; primiparous 0 vs 48.7 %; multiparous - 76.9 vs 13.4 % - P <0.0001, respectively). The response in the 5-day protocol with GnRH was worse in multiparous cows.

A presente tese foi dividida em 5 Experimentos. Os objetivos do Experimento 1 foram avaliar a utilização da gonadotrofina coriônica equina (eCG) e/ou do cipionato de estradiol (ECP) na dinâmica folicular e taxa de concepção de vacas holandesas submetidas a inseminação em tempo fixo (IATF). No D0, todos os animais (n = 782) receberam 2 mg de benzoato de estradiol (BE) e um dispositivo intravaginal de progesterona (CIDR). Oito dias depois, o CIDR foi retirado e todos os animais receberam PGF2?. Simultaneamente, os animais foram divididos em 4 grupos: G1) eCG + ECP no Dia 8; G2) eCG no Dia 8 + GnRH após 48h; G3) ECP no Dia 8; G4) GnRH após 48h. Amostras de sangue e exames utlra-sonográficos foram realizados frequentemente em um subgrupo de animais (n = 96). As análises estatísticas de todos os experimentos foram efetuadas com o proc GLIMMIX e proc MIXED do SAS. O uso de eCG e o escore de condição corporal (ECC) dos animais afetaram as concentrações circulantes de progesterona no diestro. Os animais do G2 apresentaram maior taxa de concepção que os do G4 (33,8% vs. 28,9%). Além disso, para animais de menor ECC, ficou evidente o benefício da aplicação de eCG (G2 = 44,4% vs. G4 = 6,1%). No Experimento 2 (n = 26), o objetivo foi comparar o efeito da administração da eCG no dia da remoção do CIDR em animais de menor (2,0-2,5) ou maior (3,0-3,5) ECC. Foram avaliadas algumas características do corpo lúteo (CL) como o volume e histologia, assim como as concentrações plasmáticas de progesterona no diestro. Independentemente da condição corporal dos animais, a eCG aumentou o volume do CL e a concentração plasmática de progesterona no diestro. O ECC afetou negativamente o volume e concentração de progesterona sérica no diestro. Não foi encontrado diferença na proporção de células grandes/pequenas, assim como no fluxo sanguíneo no CL entre os grupos experimentais. No Experimento 3, foi comparado a taxa de concepção em vacas de leite de alta produção (n = 388) após o uso do protocolo G2 do Experimento 1 (Capítulo I), com ou sem adição de ECP no momento da retirada do CIDR (novo ou usado). Não foi verificado efeito da adição do tratamento com ECP e nem do tipo do dispostivo na taxa de concepção. No Experimento 4 (n = 199), apesar no aumento verificado no diâmetro folicular no grupo tratado com GnRH 56h (17,8 mm) comparado com GnRH 48h (16,5 mm); e do atraso no momento da ovulação após a retirada do CIDR (GnRH 56h = 75,3h; GnRH 48h = 79,8h) não foi constatado qualquer diferença na concepção ao se atrasar a aplicação do GnRH de 48h para 56h em vacas inseminadas 16h depois do GnRH. No Experimento 5 (n = 185), a taxa de concepção não diferiu em animais que receberam o GnRH 48h ou 56h (momento da IATF) após a retirada do CIDR, indicando a possibilidade do emprego de um protocolo com apenas 3 manejos em vacas de leite de alta produção. / The current thesys has been divided in 5 Experiments. Objectives of Experiment 1 were to evaluate the effects of equine chorionic gonadotropin (eCG) and/or estradiol cypionate (ECP) on follicular dymanics and conception rate in Holstein cows receiving fixed timed artificial insemination (TAI). On D0, all cows (n = 782) received 2 mg of estradiol benzoate (EB) and one intravaginal progesterone device (CIDR). Eight days later, CIDR was removed and all animals were treated with PGF2?. Simultaneously, animals were divided in 4 groups: G1) eCG + ECP on Day 8; G2) eCG on Day 8 + GnRH 48h later; G3) ECP on Day 8; G4) GnRH 48h later. Blood samples and ultrasound exams were frequently performed in a subset of the animals (n = 96). All the statistical analyses for all experiments were performed with proc GLIMMIX and proc MIXED of SAS. Equine chorionic gonadotropin (eCG) treatment and body condition score (BCS) affected circulating progesterone in the diestrus. Cows in G2 had greater conception rates than cows in G4 (33,8% vs. 28,9%). In addition, in cows with lower BCS, eCG seems to be even more affective (G2 = 44,4% vs. G4 = 6,1%). In Experiment 2 (n = 26), the objective was to compare the effect of eCG the day of CIDR removal in animals with lower (2,0-2,5) or higher (3,0-3,5) BCS. Some variables such as corpus luteum (CL) volume, histology and circulating progesterone concentration in the diestrus were evaluated. Regardless of the body condition of the animals, eCG increased CL volume and circulating progesterone concentration in the diestrus. BCS negatively affected CL volume and circulating progesterone. There were no differences in large/small CL cell ratio, as well as CL blood flow between experimental groups. In Experiment 3, it was compared conception rate in dairy cows (n = 388) after using the same protocol G2 from Experiment 1 (Chapter I), with or without an ECP treatment at the time of CIDR (new or used) removal. Both ECP treatment and type of CIDR did not significantly affected conception rates. In Experiment 4 (n = 199), despite the fact that follicular diameter was increased in group GnRH 56h (17,8 mm) compared with GnRH 48h (16,5 mm); and of the delayed time of ovulation after CIDR removal (GnRH 56h = 75,3h; GnRH 48h = 79,8h), there were no differences in conception rates after delaying the GnRH treatment from 48h to 56h in cows inseminated 16h after GnRH. In Experiment 5 (n = 185), conception rate did not differ in animals that received GnRH 48h or 56h (at the time of TAI) after CIDR removal, indicating the possibility of using a protocol with only 3 handlings in high producing dairy cows.

A transferência de embriões (TE) é uma biotecnologia amplamente utilizada na produção de equinos no Brasil, e a égua receptora exerce um papel fundamental nos resultados finais nos programas de reprodução. Alguns tratamentos têm sido preconizados com objetivo de exercer ação luteotrófica, melhorando a função luteal, e com isto aumentando os níveis sistêmicos de progesterona, como também o uso de drogas anti-inflamatórias, que evitam a perda da função luteal causada pela liberação de prostaglandina em processos inflamatórios prévios ou por manipulação na passagem transcervical do embrião no momento da TE. O objetivo deste estudo foi investigar os efeitos do anti-inflamatório inibidor seletivo COX 2 (meloxicam) associado ao uso luteotrófico da hCG na gestação, características de corpo lúteo, fertilidade e desenvolvimento embrionário em éguas receptoras. Para isto, 60 éguas receptoras alojadas em central de reprodução foram aleatoriamente divididas em 4 grupos de 15 animais, de acordo com os seguintes tratamentos: aplicação de 5ml solução fisiológica no dia da ovulação (controle); aplicação de 2500 UI hCG no dia da ovulação; aplicação de 2500 UI hCG no dia da ovulação associado a 0,6 mg/kg de meloxicam; aplicação de 2500 UI hCG no momento da transferência do embrião associado a 0,6 mg/kg meloxicam. No dia da TE, 7 dias após a TE e 21 dias após a TE para as éguas que ficaram gestantes, foi avaliada a irrigação do corpo lúteo por ultrassonografia modo doppler colorido por meio de score do percentual de irrigação (0-100%), e a irrigação do útero avaliado por score (1-4). Por meio da ultrassonografia no modo B, a área do CL em mm2 foi avaliada nos mesmos momentos, a área da vesícula em mm2 aos 15 e 21 dias da gestação e o tamanho do embrião em cm aos 29 dias de gestação. Além disso, foi realizada dosagem plasmática de progesterona no dia da TE, 7 dias após a TE e 21 dias para as éguas gestantes. As comparações entre os grupos foram analisadas para efeitos principais de tratamento e tempo, assim como para efeito de interação tratamento x tempo. Não foi observado influencia da aplicação de hCG e/ou meloxicam nos animais tratados comparados ao controle (P&gt;0,05). No entanto, foi observado um aumento numérico na taxa de gestação para os dois grupos de receptoras que receberam anti-inflamatório meloxicam, correspondendo a um índice superior em 13,3 % de gestação para éguas tratadas. Em conclusão, não há influencia da aplicação de hCG associado ou não meloxicam sobre a perfusão sanguínea uterina, do corpo lúteo, no desenvolvimento embrionário e nas concentrações plasmáticas de progesterona em receptoras de embriões. No entanto, existe, pela aplicação de meloxicam, evidência de melhora nos índices de gestação, podendo estar associado ao efeito anti-inflamatório seletivo COX-2, que pode melhorar resultados em programas comerciais de transferência de embriões em equinos. / Embryo transfer (ET) is a biotechnology widely used in equine production in Brazil, and the recipient mare plays a key role in the final results of breeding programs. Several treatments have been advocated both for the purpose of exerting luteotrophic action, improving luteal function, and thereby increasing systemic levels of progesterone, such as the use of anti-inflammatory drugs, which prevent the loss of luteal function caused by the release of prostaglandin in previous inflammatory processes or by manipulation in the transcervical passage of the embryo at the time of ET. The objective of this study was to investigate the effects of the anti-inflammatory COX 2 inhibitor (meloxicam) associated with luteotrophic use of hCG in gestation, corpus luteum characteristics, fertility and embryonic development in recipient mares. For this, 60 receiving mares housed in a reproduction center were randomly divided into 4 groups of 15 animals, according to the following treatments: application of 5ml physiological solution on the day of ovulation (control group); application of 2500 IU hCG on ovulation day; application of 2500 IU hCG on the day of ovulation associated with 0.6 mg/kg of meloxicam; application of 2500 IU hCG at the time of embryo transfer associated with 0.6 mg/kg meloxicam. On the day of ET, 7 days after ET and 21 days after ET for pregnant mares, corpus luteum irrigation was evaluated by color Doppler ultrasonography using a score of the percentage of irrigation (0-100%), and irrigation of the uterus evaluated by score (1-4). Using B-mode ultrasonography, corpus luteum area in mm2 was assessed at the same time points, the area of the embryonic vesicle in mm2 at 15 and 29 days of gestation, and the size of the embryo in cm at 29 days of gestation. In addition, plasma progesterone dosage was performed on ET day 7 days after ET in all groups and 21 days after ET for pregnant mares. The comparisons between the groups were analyzed for main effects of treatment and time, as well as for interaction effect treatment x time. No influence of application of hCG and / or meloxican was observed on treated animals compared to control (P&gt;0.05). However, a numerical increase in gestation rate was observed for the two groups of recipients who received anti-inflammatory meloxicam, corresponding to an index higher than 13.3% of gestation for treated mares. In conclusion, there is no influence of the application of hCG associated or not to meloxicam on uterine irrigation, corpus luteum, embryo development and plasma concentrations of progesterone in embryo recipients. However, there is evidence of improvement in gestation rates due to the application of meloxicam, which may be associated with the COX-2 selective anti-inflammatory effect of this drug, improving results in commercial embryo transfer programs in horses.

La sclérose en plaques (SEP) est une maladie démyélinisante dont les causes ne sont pas encore bien élucidées. Cependant, l’implication des réponses auto-immunes dans la mort des oligodendrocytes engendrant la destruction des gaines de myéline et le disfonctionnement axonal est bien documentée. Les thérapies actuelles utilisant des agents anti-inflammatoires et immunomodulateurs ciblent la réduction de l’inflammation et la progression de la maladie, mais leur efficacité reste limitée et décroit après un long traitement. Toutefois, une nouvelle stratégie de traitement, basée sur la capacité endogène du cerveau à réparer la myéline, commence à voir le jour.L’utilisation des hormones stéroïdes offre une grande opportunité, compte tenu de leurs actions pléiotropiques à la fois au cours du développement et chez les sujets adultes. Notre étude montre que les androgènes et les progéstagènes jouent un rôle très important dans la prolifération des oligodendrocytes et dans la réparation de la myéline. Ces stéroïdes permettent une remyélinisation au niveau des cultures organotypiques du cervelet de souris ou de rats après une démyélinisation par la lysolécithine. En outre, l’utilisation des souris knock-out pour le récepteur de la progestérone (PR-KO) montre l’importance de ce récepteur dans l’effet promyélinisant de la progestérone. De même, l’effet pro-remyélinisant des androgènes passe par l’intermédiaire de leur récepteur nucléaire (AR) puisque la Flutamide, agent antagonisant ces récepteurs, aboli complétement cette action. De même, l’utilisation des souris knock-out pour le récepteur de la progestérone montre l’importance de ce récepteur dans l’effet promyélinisant de la progestérone.L’influence de la testostérone et des ces métabolites sur la réparation de la myéline au niveau du corps calleux est aussi montrée in vivo, en traitant les souris C57Bl/6 par la cuprizone pendant 12 à 14 semaines. Le traitement de ces souris par la testostérone ou ces métabolites 5α- dihydrotestosterone (5α-DHT), 17β-estradiol ou par un agoniste synthétique fort, le 7α-methyl-19-nortestosterone (MENT) pendant 6 semaines, induit un remarquable recrutement des progéniteurs d’oligodendrocytes, suivie par une importante remyélinisation des zones démyélinisées. Le mécanisme d’action de ces androgènes implique le récepteur AR puisque aucun effet promyélinisant n’a été observé chez les souris dont l’AR est muté (tfm : testicular feminization mutation) et les souris ARNes/cre (mutation conditionnelle de l’AR dans les neurones et les cellules macrogliales). Les souris ArKO (Aromatse Knoctout) ne pouvant pas convertir la testostérone en estradiol sont aussi insensibles au traitement par la testérone.Ces travaux montrent que les stéroïdes jouent un rôle très important dans la remyélinisation in vitro et in vivo, fournissant une preuve expérimentale pour une utilisation des stéroïdes dans des essais cliniques futurs visant à réparer la myéline. / Multiple sclerosis (MS) is a very prominent demyelinating disease. The cause of demyelination in MS is not clear, however, it involves autoimmune responses and the death of oligodendrocytes accompanied by myelin destruction and axonal dysfunction. Currently available therapies including anti-inflammatory agents and immunomodulators are targeted to reduce inflammation and disease progression but their limited efficacy further decrease after prolonged treatment.However, another therapeutic strategy has gained recently much interest, is to boost the endogenous capacity of the brain to repair myelin.Steroid hormones offer an opportunity for therapeutic interventions in a wide range of tissue abnormalities because of their multiple actions during development and in adulthood. Our studies show that androgens and progestagens play pivotal role in oligodendrocyte proliferation and subsequent myelination. Androgens or progestagens promote remyelination after lysolecithin mediated myelin insult of organotypic cerebellar slices in culture. Moreover, remyelinating effects of testosterone can be blocked by flutamide, an androgen receptor (AR) inhibitor. Also, the remyelination induced by progestagens is abolished when cerebellar slices are used from progesterone receptors (PR) knockout mice.The influence of testosterone and its metabolites on myelin repair was also evident in toxininduced demyelination in vivo. Long-term cuprizone intoxication (12-14 weeks) of adult C57Bl/6 mice caused chronic and severe demyelination in the corpus callosum. Treatment of these mice with testosterone or its metabolites, particularly 5α-dihydrotestosterone (5α-DHT), estradiol-17β and potent testosterone analog 7α-methyl-19-nortestosterone (MENT) for 6 weeks results in a marked replenishment of the corpus callosum with oligodendrocytes and remyelination. Testosterone fails to stimulate remyelination in mice carrying testicular feminization mutation (Tfm) of AR in the cuprizone model. Furthermore, we demonstrate that testosterone directly targets neuronal and macroglial AR, because the specific ablation of neural AR in (ARNes/Cre) mice prevents the myelin repair in response to testosterone. Interestingly, blocking the conversion of testosterone into estrogens by knocking out the aromatase gene (ArKO mice), also impair the remyelinating effect of testosterone.In conclusion, we provide a strong evidence for a new role of progestagens and androgens in remyelination and thus present a sound experimental support for future clinical trials based on steroid hormone therapy for demyelinating disorders.